Sensorion receives ANSM authorization to start SENS-601 trial in France
Sensorion said the ANSM has authorized it to initiate its Hear… clinical trial in France for SENS-601, its investigational gene therapy for GJB2-related hearing loss.
Regulatory News:Sensorion (FR0012596468 — ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, today announced that it has received authorization from the ANSM to initiate Hear…